Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2014Título de revista
Haematologica
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)